Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImExHSASX:IME 52 14-Day RSI is 38.73 as of Jul. 14, 2026. GuruFocus rates ASX:IME with a GF Score™ of 52/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, ImExHS ranks better than 77.42% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-14), ImExHS's 14-Day RSI is 38.73.
The industry rank for ImExHS's 14-Day RSI or its related term are showing as below:
ASX:IME's 14-Day RSI is ranked better than 77.42% of 217
companies
in the Medical Diagnostics & Research industry
Industry Median: 48.59
vs ASX:IME: 38.73
ImExHS (ASX:IME) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
ImExHS 14-Day RSI Related Terms
ASX:IME vs TMO, DHR, IDXX: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, ImExHS's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImExHS 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ImExHS's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where ImExHS's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImExHS (ASX:IME) has a 14-Day RSI of 38.73 as of Jul. 14, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on ImExHS and its competitors. According to the industry distribution chart, ImExHS ranks #49 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 22.6%.
Is ImExHS's 14-Day RSI too high?
ImExHS's current 14-Day RSI is 38.73. The Medical Diagnostics & Research industry median 14-Day RSI is 48.59. ImExHS's value of 38.73 is 20.3% below this industry median. Based on the distribution chart, ImExHS ranks #49 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, ImExHS has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImExHS's 14-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ImExHS ranks #49 out of 217 companies for 14-Day RSI. This places ImExHS in the top 23% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 48.59. ImExHS's value of 38.73 is 20.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 48.59, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImExHS's current 14-Day RSI of 38.73 is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on ImExHS and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 48.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImExHS's current 14-Day RSI is 38.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImExHS stock overvalued right now?
Based on GuruFocus' analysis, ImExHS (ASX:IME) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.31 — trading 39.2% below its estimated fair value. The current 14-Day RSI is 38.73 and 20.3% below the Medical Diagnostics & Research industry median of 48.59. ImExHS's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For ImExHS (ASX:IME), the current 14-Day RSI is 38.73 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImExHS (ASX:IME) Overvalued in 2026?
Based on GuruFocus' analysis, ImExHS stock appears to be undervalued.
The current stock price of A$0.31 is trading 39.2% below its estimated GF Value™ of A$0.51.
GuruFocus considers ImExHS to be Possible Value Trap.
Key valuation signals for ASX:IME:
14-Day RSI: 38.73
GF Value™: A$0.51 vs. price of A$0.31 (39.2% below fair value)
Industry Position: 20.3% below the Medical Diagnostics & Research median (#49 of 217)
No single metric tells the full story. See the ASX:IME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImExHS Ltd is a healthcare technology company engaged in the provision of medical imaging software and radiology services. The company develops and delivers enterprise imaging solutions, including radiology information systems and picture archiving and communication systems, as well as provides diagnostic imaging and teleradiology services to healthcare institutions. The company operates through two reportable segments: Software, which focuses on the development and sale of imaging systems and platforms, and Radiology Services, which provides diagnostic and teleradiology services to hospitals and medical facilities. It generates the majority of its revenue from the Radiology segment.
52GF Score
Get the complete analysis for ASX:IME
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IME has been successfully added to your 
